Engineering enhanced CAR T-cells for improved cancer therapy

Michael C Milone; Jie Xu; Sai-Juan Chen; McKensie A Collins; Jianfeng Zhou; Daniel J Powell Jr; J Joseph Melenhorst

doi:10.1038/s43018-021-00241-5

Engineering enhanced CAR T-cells for improved cancer therapy

Nat Cancer. 2021 Aug;2(8):780-793. doi: 10.1038/s43018-021-00241-5. Epub 2021 Aug 19.

Authors

Michael C Milone^{1

2}, Jie Xu^{1

2

3}, Sai-Juan Chen³, McKensie A Collins^{1

2}, Jianfeng Zhou⁴, Daniel J Powell Jr^{1

2}, J Joseph Melenhorst^{1

2}

Affiliations

¹ Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
² Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
³ Department of Hematology, Shanghai Institute of Hematology, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.
⁴ Immunotherapy Research Center for Hematologic Diseases of Hubei Province, PR China.

Abstract

Chimeric antigen receptor (CAR) T-cell therapies have evolved from a research tool to a paradigm-shifting therapy with impressive responses in B cell malignancies. This review summarizes the current state of the CAR T-cell field, focusing on CD19- and B cell maturation antigen-directed CAR T-cells, the most developed of the CAR T-cell therapies. We discuss the many challenges to CAR-T therapeutic success and innovations in CAR design and T-cell engineering aimed at extending this therapeutic platform beyond hematologic malignancies.

Keywords: CAR; T cell; antigen; cancer; chimeric.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Antigens, CD19
Humans
Immunotherapy, Adoptive
Neoplasms* / therapy
Receptors, Chimeric Antigen*
T-Lymphocytes

Substances

Antigens, CD19
Receptors, Chimeric Antigen

Abstract

Publication types

MeSH terms

Substances

Grants and funding